Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor

• Published in: Biochemical and biophysical research communications Vol. 382; no. 3; pp. 535 - 539
• Main Authors: Lopes, Luciana B., Flynn, Charles, Komalavilas, Padmini, Panitch, Alyssa, Brophy, Colleen M., Seal, Brandon L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.05.2009
• Subjects: Amino Acid Sequence; Cell Membrane Permeability; Cells, Cultured; Collagen type I; CTGF; Heat shock protein 27; HSP27 Heat-Shock Proteins - metabolism; HSP27 phosphorylation; Humans; Intracellular Signaling Peptides and Proteins - antagonists & inhibitors; Keloid fibroblast; MAPKAP Kinase 2; Molecular Sequence Data; Peptide inhibitor; Peptides - metabolism; Peptides - pharmacology; Phosphorylation - drug effects; Protein Kinase Inhibitors - metabolism; Protein Kinase Inhibitors - pharmacology; Protein-Serine-Threonine Kinases - antagonists & inhibitors; TGF-β1; Transforming Growth Factor beta1 - antagonists & inhibitors; Transforming Growth Factor beta1 - pharmacology; MAPKAP Kinase 2; Keloid fibroblast; Peptide inhibitor; Collagen type I; TGF-β1; Heat shock protein 27; HSP27 phosphorylation; CTGF
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2009.03.056

Heat shock protein 27 (HSP27) has been implicated in many intracellular signaling processes. Since the phosphorylation of HSP27 can modulate its activity, the ability to inhibit phosphorylation of HSP27 might have clinical relevance especially with regard to the treatment of fibrosis. We have developed a cell-permeant peptide inhibitor of MAPKAP Kinase 2 (MK2), an enzyme that phosphorylates HSP27, by combining a previously described peptide substrate of MK2 with a cell penetrating peptide. This novel MK2 inhibitor (MK2i) reduced HSP27 phosphorylation by MK2 in vitro. At 10 μM, MK2i inhibited TGF-β1-induced HSP27 phosphorylation in serum-starved human keloid fibroblasts. In addition, 10 μM MK2i decreased TGF-β1-induced expression of connective tissue growth factor and collagen type I within serum-starved keloid fibroblasts. Thus, MK2i represents a potential therapeutic for the treatment of fibrotic disorders.